<DOC>
	<DOCNO>NCT02992288</DOCNO>
	<brief_summary>The objective study find optimal dose daily oral neladenoson bialanate ( BAY 1067197 ) give addition standard therapy heart failure reduce ejection fraction ( HFrEF ) .</brief_summary>
	<brief_title>A Trial Study Neladenoson Bialanate Over 20 Weeks Patients With Chronic Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adenosine A1 Receptor Agonists</mesh_term>
	<criteria>Men woman age 18 year old Diagnosis chronic heart failure ( CHF ) , NYHA ( New York Heart Association ) class IIIV , LVEF â‰¤ 35 % elevate NTproBNP Acute denovo heart failure Requirement intravenous ( IV ) treatments follow 48 hour prior randomization Mechanical support ( e.g . intraaortic balloon pump , endotracheal intubation , mechanical ventilation , ventricular assist device ) Any cause chronic heart failure ischemic cardiomyopathy idiopathic dilate cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Heart Failure Reduced Ejection Fraction</keyword>
</DOC>